HLB innoVation Decides to Invest Additional KRW 41.4 Billion in US Subsidiary VERISMO for Clinical Trials, No Dilution to Existing Shareholders
HLB innoVation decided to acquire an additional 5,283,018 shares of its US subsidiary VERISMO THERAPEUTICS through a third-party allotment capital increase totaling KRW 41.47 billion, aimed at funding clinical trials and operational expenses.
The acquisition will slightly increase HLB innoVation's stake in VERISMO from 98.75% to 98.93%, further strengthening control over the subsidiary.
The funding comes from internal cash reserves, and since there is no change in HLB innoVation's outstanding shares, existing shareholders face no dilution.
However, VERISMO recorded a net loss of KRW 37.15 billion in 2025, indicating persistent losses, making this investment a defensive capital allocation focused on long-term pipeline value rather than short-term profitability.
The acquisition amount represents 18.74% of HLB innoVation's equity capital, a significant financial commitment, but the ratio to total assets is 15.43% suggesting manageable risk.
As of June 25, 2026, a total of 1,132,074 shares from the first two tranches have been acquired, with the remaining shares expected to be paid by December 31, 2026.
[AI Summary]HLB innoVation's additional KRW 41.4 billion investment in subsidiary VERISMO does not dilute existing shareholders due to no change in its own shares. However, the subsidiary's continuous losses and high investment relative to equity pose financial burdens. The near-term stock price impact is neutral, but mid-to-long-term volatility depends on clinical outcomes.
KOSDAQ Filing Information
[Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations